|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
CO-ADMINISTRATION WITH OTHER ANTIHYPERTENSIVES MAY RESULT IN ADDITIVE EFFECT OR POTENTIATION
|
CO-ADMINISTRATION WITH OTHER ANTIHYPERTENSIVES MAY RESULT IN ADDITIVE EFFECT OR POTENTIATION
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY IN PATIENTS WHOSE RENAL FUNCTION DEPENDS UPON ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERON SYSTEM EG. PATIENTS WITH SEVERE CHF
|
POSSIBILITY OF EXCESSIVE REDUCTION IN BLOOD PRESSURE
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
ENALAPRIL MAY POTENTIATE THE SYSTEMIC SIDE EFFECTS SEEN WITH THE INTRAVENOUS IRON THERAPY
|
ENALAPRIL MAY POTENTIATE THE SYSTEMIC SIDE EFFECTS SEEN WITH THE INTRAVENOUS IRON THERAPY
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
POTENTIAL FOR SIGNIFICANT HYPERKALEMIA ; POSSIBILITY OF EXCESSIVE REDUCTION IN BLOOD PRESSURE
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION WITH OTHER ANTIHYPERTENSIVES MAY RESULT IN ADDITIVE EFFECT OR POTENTIATION
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
POSSIBILITY OF EXCESSIVE REDUCTION IN BLOOD PRESSURE
|
POTENTIAL FOR REVERSIBLE LITHIUM TOXICITY ; FREQUENT MONITORING OF LITHIUM LEVELS IN RECOMMENDED
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
CO-ADMINISTRATION OF NSAIDS AND ACE INHIBITORS MAY POTENTIATE RENAL DISEASE STATES
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT & HYPERKALEMIA
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT & HYPERKALEMIA
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
CO-ADMINISTRATION MAY RESULT IN INCREASED HYPOTENSIVE EFFECT
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
POTENTIAL FOR SIGNIFICANT HYPERKALEMIA ; POSSIBILITY OF EXCESSIVE REDUCTION IN BLOOD PRESSURE
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|